



July 27, 2020

Financial Reporting
British Columbia Securities Commission

Dear Sir/Madam,

Following a review conducted by the Corporate Disclosures department at the British Columbia Securities Commission due to Abattis Bioceuticals Corp (“Abattis” or the “Company”) failure to file its required financial statements within the 90 day filing deadline required under National Instrument 51-102 – *Continuous Disclosure Requirements*, the Company was required to make amendments to its interim Management Discussion and Analysis for interim ended June 30, 2019.

The following filings have been updated:

Project Number – 02960604 – Interim MD&A

Project Number – 02960606 – Interim Certificates (NI 52-109)

Yours truly,

“Rob Abenante”

Robert Abenante
Chief Executive Officer